Nitrase Therapeutics
PrivateLast Round
Grant
Apr 5, 2022
Total Funding Raised
$84.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nitrase Therapeutics is a biopharmaceutical company that develops therapies targeting a wide range of diseases by utilizing its innovative platform focused on the biochemical modification of proteins through nitration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nitrase Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Nitrase Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 5, 2022 | ||||
| Series A | Nov 2, 2021 | ||||
| Series A | Apr 21, 2020 | ||||
| Grant | Jun 12, 2019 | ||||
| Seed | Jul 12, 2018 |
Nitrase Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AbbVie Ventures | Series A |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Series A |
| Sofinnova Partners | Series A |
| Mission Bay Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 56% MoM.
- Mar 20, 2025
Discovered glyoxalase domain-containing protein 4 (GLOD4), which catalyzes selective protein nitration.
Nitrase Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nitrase Therapeutics's valuation, stock price, and market status.